GeneFerm Biotechnology Co. Ltd.
TTPEX:179627.85
TWD
-0.35
(-1.24%)
ISIN
TW0001796001
Return %
Stock
S&P 500
1Y
-45.28
14.20
3Y
-63.26
81.12
5Y
-24.01
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Chin Te Chin
- Full Time Employees
- 288
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No.3, Dali 2nd Rd. Tainan TQ Taiwan 741014
- IPO Date
- Jul 26, 2016
- Website
- geneferm.com
- Similar Companies
- Business
- GeneFerm Biotechnology Co., Ltd. is a Taiwan-based biotechnology company specializing in microbial fermentation toll manufacturing and the production of bio-fermented functional ingredients and health supplements. Founded in 1999 and headquartered in Tainan, Taiwan, the company provides precision fermentation and biomass fermentation contract development and manufacturing organization (CDMO) services, supported by advanced large-scale fermentation facilities including commercial-scale fermenters and downstream processing equipment. Its core products include probiotics such as GFRena2 and TestoPro; bioactive fermented ingredients like AquaSoiivon soy extract ferment; health food items including nattokinase, red yeast rice, medicinal fungi, herbal extracts; and animal-derived products such as marine collagen peptide and d-glucosamine powder. GeneFerm's offerings cater to international pharmaceutical, biotechnology, food companies, as well as novel foods and farming supplements markets across Taiwan, the USA, Australia, Japan, Israel, Belgium, and other regions. In the last 1-2 years, GeneFerm has introduced notable innovations and received several patents. It launched the GFRena2 probiotic, which has six major patents and demonstrated efficacy through multiple international journal publications, featuring advanced coating and rapid freezing technologies to ensure probiotic viability and high survival rates in production, storage, and application. The company also developed AquaSoiivon™, a soy extract ferment with enhanced bioavailability, granted five patents in Taiwan and the U.S. Additionally, it collaborated with National Taiwan University to license TestoPro, a functional probiotic strain awarded the 20th National Innovation Award, which supports physiological regulation via enterohepatic circulation. GeneFerm has obtained various international certifications including ISO 9001, ISO 22000, HACCP, FSSC22000, KOSHER, and HALAL to ensure high manufacturing standards. It is actively expanding its precision fermentation manufacturing capacity to meet growing global demand. GeneFerm operates primarily within the biotechnology and health food sectors, focusing on precision and biomass fermentation services, microbial fermentation toll manufacturing, contract manufacturing, and ODM/OEM customized finished health products. Its target customers include pharmaceutical, biotech, and food industry clients worldwide. The company maintains a strong R&D footprint with capabilities in strain screening, medium optimization, fermentation strategy, and extraction and purification processes, positioning itself as a master of microbial fermentation dedicated to sustainable production and quality assurance in the fermented health product space.